COST-EFFECTIVENESS OF FRACTURE PREVENTION IN ESTABLISHED OSTEOPOROSIS

被引:67
|
作者
JONSSON, B
CHRISTIANSEN, C
JOHNELL, O
HEDBRANDT, J
机构
[1] CTR CLIN & BASIC RES,BALLERUP,DENMARK
[2] MALMO GEN HOSP,DEPT ORTHOPED,S-21401 MALMO,SWEDEN
[3] LINKOPING UNIV,SYST ANAL GRP,LINKOPING,SWEDEN
关键词
COST-EFFECTIVENESS; FRACTURE; MODEL; OSTEOPOROSIS; PREVENTION;
D O I
10.1007/BF01623315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study presents the results of a computer simulation model for calculating the cost-effectiveness and cost-utility of treating patients with established osteoporosis in order to reduce the risk of fractures. The results are based on Swedish data for risk of fracture and costs. The treatment intervention modelled is based on treatment of a 62-year-old woman with established osteoporosis. The cost per hip fracture avoided is 350 000 SEK, assuming a 50% reduction in the risk of fracture due to 5 years of treatment. A sensitivity analysis for changes in the cost and effectiveness of treatment, the risk of fracture and the discount rate is performed. The cost per life-year gained and the cost per quality-adjusted life-year (QALY) gained is presented to enable comparison of the cost-effectiveness of treating osteoporosis with that of other health care interventions. A comparison between treating the same woman for osteoporosis and mild hypertension shows a cost per Life-year gained of 220 000 SEK and 128 000 SEK respectively. Cost per QALY gained is very similar for the two interventions:105 000 SEK and 103 000 SEK respectively. This model provides a tool to enable clinicians, administrators and health policy makers to analyze and understand the economic aspects of a major health policy issue.
引用
收藏
页码:136 / 142
页数:7
相关论文
共 50 条
  • [21] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J. A. Kanis
    F. Borgstrom
    O. Johnell
    B. Jonsson
    Osteoporosis International, 2004, 15 : 862 - 871
  • [22] Cost-effectiveness analysis of biphosphonates and raloxifene for treatment of osteoporosis and prevention of fractures
    Lau, TC
    Lim, BP
    Li, SC
    VALUE IN HEALTH, 2005, 8 (03) : 408 - 408
  • [23] Cost-effectiveness of bisphosphonates in the prevention of corticosteroid-induced osteoporosis.
    Jacobs, HJ
    Suarez-Almazor, P
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S303 - S303
  • [24] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    Kanis, JA
    Borgstrom, F
    Johnell, O
    Jonsson, B
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (11) : 862 - 871
  • [25] A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN: A COMPARISON OF SEVEN TREATMENT OPTIONS
    Pongchaiyakul, C.
    Songpattanasilp, T.
    Taechakraichana, N.
    VALUE IN HEALTH, 2010, 13 (07) : A558 - A558
  • [26] Role of prevention: cost-effectiveness of prevention
    Berrino, F
    ANNALS OF ONCOLOGY, 2004, 15 : 245 - 248
  • [27] Avahan and the cost-effectiveness of "prevention as prevention"
    Marseille, Elliot
    Kahn, James G.
    LANCET GLOBAL HEALTH, 2014, 2 (09): : E493 - E494
  • [28] Bridging the Osteoporosis Treatment Gap: Performance and Cost-Effectiveness of a Fracture Liaison Service
    Yates, Christopher J.
    Chauchard, Marie-Anne
    Liew, Danny
    Bucknill, Andrew
    Wark, John D.
    JOURNAL OF CLINICAL DENSITOMETRY, 2015, 18 (02) : 150 - 156
  • [29] COST-EFFECTIVENESS OF SCREENING WOMEN FOR OSTEOPOROSIS
    TOSTESON, AA
    ROSENTHAL, DI
    WEINSTEIN, MC
    MEDICAL DECISION MAKING, 1987, 7 (04) : 281 - 281
  • [30] The cost-effectiveness of alendronate in the management of osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    BONE, 2008, 42 (01) : 4 - 15